Colorectal cancer diagnosis kit has granted patent for inventions

REColonTM, an non-invasive colorectal cancer diagnosis, has been granted patent for inventions in China in August, 2017.


REColonTM is the 1st CRC molecular diagnostic product that uses miR-92a as biomarker from China. MicroRNA has good stability and repeatability in stool1. MiR-92a, a small non-coding RNA, is located at human chromosome 13 miR-17-92 gene cluster. MiR-92a promotes the CRC cell proliferation and migration by targeting PTEN, KLF4 and p21 genes1. Compared with normal population, the miR-92a level was significantly increased in stool of individuals with CRC lesions and CRC patients2,3. Hence, miR-92a could be used as a sensitive and specific molecular biomarker for CRC diagnostics


国家发明专利.jpg


ReTREColonTM miR-92a assay kit is jointly developed by Shenzhen GeneBioHealth Co., Ltd and The Chinese University of Hong Kong. The miR-92a assay technology was awarded the 2nd prize of the National Natural Science Award of China in 2017. REColonTM is a quantitative real-time PCR detection of miR-92a in human stool specimen. REColonTM achieves 71.76% sensitivity and 90.07% specificity for CRC diagnosis. By co-working with existing clinical tests, REColonTM serves as an effective tool for CRC screening, early diagnosis and postoperative monitoring.


References:

1. Schreuders, E. H. et al. Colorectal cancer screening: a global overview of existing programmes. Gut 64, 1637-1649, doi:10.1136/gutjnl-2014-309086 (2015).

2. Zhu, J. et al. Epidemiological Trends in Colorectal Cancer in China: An Ecological Study. Digestive diseases and sciences 62, 235-243, doi:10.1007/s10620-016-4362-4 (2017).

3. Chen, W. et al. Cancer statistics in China, 2015. CA: a cancer journal for clinicians 66, 115-132, doi:10.3322/caac.21338 (2016).

REColonTM, an non-invasive colorectal cancer diagnosis, has been granted patent for inventions in China in August, 2017.


REColonTM is the 1st CRC molecular diagnostic product that uses miR-92a as biomarker from China. MicroRNA has good stability and repeatability in stool1. MiR-92a, a small non-coding RNA, is located at human chromosome 13 miR-17-92 gene cluster. MiR-92a promotes the CRC cell proliferation and migration by targeting PTEN, KLF4 and p21 genes1. Compared with normal population, the miR-92a level was significantly increased in stool of individuals with CRC lesions and CRC patients2,3. Hence, miR-92a could be used as a sensitive and specific molecular biomarker for CRC diagnostics


ReTREColonTM miR-92a assay kit is jointly developed by Shenzhen GeneBioHealth Co., Ltd and The Chinese University of Hong Kong. The miR-92a assay technology was awarded the 2nd prize of the National Natural Science Award of China in 2017. REColonTM is a quantitative real-time PCR detection of miR-92a in human stool specimen. REColonTM achieves 71.76% sensitivity and 90.07% specificity for CRC diagnosis. By co-working with existing clinical tests, REColonTM serves as an effective tool for CRC screening, early diagnosis and postoperative monitoring.


References:

1. Schreuders, E. H. et al. Colorectal cancer screening: a global overview of existing programmes. Gut 64, 1637-1649, doi:10.1136/gutjnl-2014-309086 (2015).

2. Zhu, J. et al. Epidemiological Trends in Colorectal Cancer in China: An Ecological Study. Digestive diseases and sciences 62, 235-243, doi:10.1007/s10620-016-4362-4 (2017).

3. Chen, W. et al. Cancer statistics in China, 2015. CA: a cancer journal for clinicians 66, 115-132, doi:10.3322/caac.21338 (2016).


服务热线:
0755-86573093
企业简介
资料中心
肠癌科普
深圳市晋百慧生物有限公司
传真:0755-86573069   邮箱:market@genebiohealth.com   地址:深圳南山区桃源街道田寮工业A区9栋二楼西面
Copyright ©2018 深圳市晋百慧生物有限公司 版权所有 粤ICP备15109924号

扫码关注我们